Hedge fund billionaire Daniel Loeb slashed his stake in the consumer health company Kenvue Inc. (NYSE:KVUE) at Third Point LLC in the fourth quarter of FY25.
As of Dec. 31, 2025, Loeb reduced his stake in the company by 64% to 3.25 million shares from about 9.0 million shares in the third quarter of 2025.
Notably, Kenvue was formerly a part of Johnson & Johnson (NYSE:JNJ) before becoming an independent company in August 2023. The company's major products include several J&J brands, including Tylenol, Listerine, Neutrogena, and Nicorette.
Recent Key Events
- In February, Kenvue reported fourth-quarter earnings of 27 cents per share, which beat the consensus of 22 cents. The company reported sales of $3.780 billion, which exceeded the consensus estimate of $3.681 billion.
- The company’s Board approved an initiative to streamline its operating model, which is expected to reduce the workforce by approximately 3.5%. The program is projected to incur pre-tax restructuring and related charges of about $250 million in fiscal year 2026.
- Kenvue said it is moving forward with its acquisition process by Kimberly-Clark Corporation (NYSE:KMB). Kenvue and Kimberly-Clark shareholders overwhelmingly approved the proposals necessary for Kimberly-Clark to complete its acquisition of Kenvue, with approximately 99% of shares voted in favor at Kenvue's Special Meeting. The transaction is expected to close in the second half of 2026, pending regulatory approvals.
- In November 2025, Kimberly-Clark announced the acquisition of Kenvue at an enterprise value of about $48.7 billion.
Technical Analysis
Kenvue is sitting in the lower half of its $14.02 to $25.17 52-week range, which keeps the longer-term chart in "repair mode" after last year's slide. The stock is trading 1.2% above its 20-day simple moving average (SMA) but 0.1% below its 100-day SMA, a setup that points to short-term stabilization without a clean intermediate uptrend.
Earnings & Analyst Outlook
The countdown is on: Kenvue is set to report earnings on May 7, 2026 (confirmed).
- EPS Estimate: 26 cents (Up from 24 cents)
- Revenue Estimate: $3.85 billion (Up from $3.74 billion)
- Valuation: P/E of 23.0x (Indicates fair valuation)
Analyst Consensus & Recent Actions: The stock carries a Hold Rating with an average price target of $18.20. Recent analyst moves include:
Recent analyst moves include:
- Citigroup: Neutral (Lowers Target to $19.00) (April 15)
- Barclays: Equal-Weight (Lowers Target to $18.00) (April 14)
- UBS: Neutral (Lowers Target to $18.00) (April 7)
KVUE Stock Price Activity: Kenvue shares were down 0.14% at $17.46 at the time of publication on Friday, according to Benzinga Pro data.
Photo via Shutterstock